These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 30621015)

  • 1. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action.
    Behrangi N; Fischbach F; Kipp M
    Cells; 2019 Jan; 8(1):. PubMed ID: 30621015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
    Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
    J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
    Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Siponimod for the treatment of secondary progressive multiple sclerosis.
    Dumitrescu L; Constantinescu CS; Tanasescu R
    Expert Opin Pharmacother; 2019 Feb; 20(2):143-150. PubMed ID: 30517042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
    Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
    J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The window of opportunity for treatment of progressive multiple sclerosis.
    Sorensen PS; Fox RJ; Comi G
    Curr Opin Neurol; 2020 Jun; 33(3):262-270. PubMed ID: 32251026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis.
    Habek M; Crnošija L; Junaković A; Adamec I; Barun B; Gabelić T; Krbot Skorić M
    Clin Neurophysiol; 2021 Feb; 132(2):581-585. PubMed ID: 33461086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
    Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
    Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
    Evdoshenko EP; Neofidov NA; Bakhtiyarova KZ; Davydovskaya MV; Kairbekova EI; Kolontareva YM; Malkova NA; Odinak MM; Popova EV; Sazonov DV; Stolyarov ID; Smagina IV; Fedyanin AS; Habirov FA; Khaibullin TI; Khachanova NV; Shchukin IA; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Rouyrre N; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1157-1166. PubMed ID: 32220214
    [No Abstract]   [Full Text] [Related]  

  • 13. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1145-1156. PubMed ID: 32216597
    [No Abstract]   [Full Text] [Related]  

  • 14. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
    Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS; Kolontareva YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Cree BA; Magnusson B; Rouyrre N; Fox RJ; Giovannoni G; Vermersch P; Bar-Or A; Gold R; Piani Meier D; Karlsson G; Tomic D; Wolf C; Dahlke F; Kappos L
    Mult Scler; 2021 Sep; 27(10):1564-1576. PubMed ID: 33205682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Siponimod Exert Direct Effects in the Central Nervous System?
    Kipp M
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
    Scott LJ
    CNS Drugs; 2020 Nov; 34(11):1191-1200. PubMed ID: 33108633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
    Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
    CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
    Gajofatto A
    Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.